NCT02019069View on ClinicalTrials.gov

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 3, 2014

Primary Completion Date

December 4, 2017

Study Completion Date

December 18, 2017

Conditions
Adult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)de Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaSecondary Myelodysplastic Syndromes
Interventions
DRUG

liposomal cytarabine-daunorubicin CPX-351

Given IV

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Rondeep Brar

OTHER

NCT02019069 - CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter